1921
Volume 97, Issue 3
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

Studies designed to determine the effects of mass administration of azithromycin on trachoma have suggested that mass azithromycin distributions may also reduce the prevalence of malaria. These studies have typically examined the impact of a small number of treatments over short durations. In this prespecified substudy of a cluster-randomized trial for trachoma, we compared malaria parasitemia prevalence in 24 communities in Niger randomized to receive either annual or biannual mass azithromycin distributions over 3 years. The 12 communities randomized to annual azithromycin received three treatments during the high-transmission season, and the 12 communities randomized to biannual azithromycin received a total of six treatments: three during the high-transmission season and three during the low-transmission season. Blood samples were taken to assess malariometric indices among children in all study communities at a single time point during the high-transmission season after 3 years of the intervention. No significant differences were identified in malaria parasitemia, parasite density, or hemoglobin concentration between the annual and biannual treatment arms. When compared with annual mass azithromycin alone, additional mass azithromycin distributions given during the low-transmission season did not significantly reduce the subsequent prevalence of malaria parasitemia or parasite density after 3 years, as measured during the high-transmission season.

[open-access] This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.16-0487
2017-09-07
2017-11-23
Loading full text...

Full text loading...

/deliver/fulltext/14761645/97/3/tpmd160487.html?itemId=/content/journals/10.4269/ajtmh.16-0487&mimeType=html&fmt=ahah

References

  1. Andersen SL, Oloo AJ, Gordon DM, Ragama OB, Aleman GM, Berman JD, Tang DB, Dunne MW, Shanks GD, , 1998. Successful double-blinded, randomized, placebo-controlled field trial of azithromycin and doxycycline as prophylaxis for malaria in western Kenya. Clin Infect Dis 26: 146150.[Crossref]
  2. Chico RM, Pittrof R, Greenwood B, Chandramohan D, , 2008. Azithromycin-chloroquine and the intermittent preventive treatment of malaria in pregnancy. Malar J 7: 255.[Crossref]
  3. Noedl H, , 2006. Azithromycin combination therapy with artesunate or quinine for the treatment of uncomplicated Plasmodium falciparum malaria in adults: a randomized, phase 2 clinical trial in Thailand. Clin Infect Dis 43: 12641271.[Crossref]
  4. Rosenthal PJ, , 2016. Azithromycin for malaria? Am J Trop Med Hyg 95: 24.[Crossref]
  5. Sagara I, , 2014. Efficacy and safety of a combination of azithromycin and chloroquine for the treatment of uncomplicated Plasmodium falciparum malaria in two multi-country randomised clinical trials in African adults. Malar J 13: 458.[Crossref]
  6. Taylor WR, , 1999. Malaria prophylaxis using azithromycin: a double-blind, placebo-controlled trial in Irian Jaya, Indonesia. Clin Infect Dis 28: 7481.[Crossref]
  7. Kimani J, Phiri K, Kamiza S, Duparc S, Ayoub A, Rojo R, Robbins J, Orrico R, Vandenbroucke P, , 2016. Efficacy and safety of azithromycin-chloroquine versus sulfadoxine-pyrimethamine for intermittent preventive treatment of Plasmodium falciparum malaria infection in pregnant women in Africa: an open-label, randomized trial. PLoS One 11: e0157045.[Crossref]
  8. van Eijk AM, Terlouw DJ, , 2011. Azithromycin for treating uncomplicated malaria. Cochrane Database Syst Rev 2: CD006688.
  9. Taylor WR, , 2003. Tolerability of azithromycin as malaria prophylaxis in adults in northeast Papua, Indonesia. Antimicrob Agents Chemother 47: 21992203.[Crossref]
  10. Ward SA, Sevene EJ, Hastings IM, Nosten F, McGready R, , 2007. Antimalarial drugs and pregnancy: safety, pharmacokinetics, and pharmacovigilance. Lancet Infect Dis 7: 136144.[Crossref]
  11. Gaynor BD, , 2014. Impact of mass azithromycin distribution on malaria parasitemia during the low-transmission season in Niger: a cluster-randomized trial. Am J Trop Med Hyg 90: 846851.[Crossref]
  12. Hart JD, Edwards T, Burr SE, Harding-Esch EM, Takaoka K, Holland MJ, Sillah A, Mabey DC, Bailey RL, , 2014. Effect of azithromycin mass drug administration for trachoma on spleen rates in Gambian children. Trop Med Int Health 19: 207211.[Crossref]
  13. Sadiq ST, Glasgow KW, Drakeley CJ, Muller O, Greenwood BM, Mabey DC, Bailey RL, , 1995. Effects of azithromycin on malariometric indices in The Gambia. Lancet 346: 881882.[Crossref]
  14. Schachterle SE, Mtove G, Levens JP, Clemens E, Shi L, Raj A, Dumler JS, Munoz B, West S, Sullivan DJ, , 2014. Short-term malaria reduction by single-dose azithromycin during mass drug administration for trachoma, Tanzania. Emerg Infect Dis 20: 941949.[Crossref]
  15. Stare D, Harding-Esch E, Munoz B, Bailey R, Mabey D, Holland M, Gaydos C, West S, , 2011. Design and baseline data of a randomized trial to evaluate coverage and frequency of mass treatment with azithromycin: the Partnership for Rapid Elimination of Trachoma (PRET) in Tanzania and The Gambia. Ophthalmic Epidemiol 18: 2029.[Crossref]
  16. Amza A, , 2012. Community risk factors for ocular Chlamydia infection in Niger: pre-treatment results from a cluster-randomized trachoma trial. PLoS Negl Trop Dis 6: e1586.[Crossref]
  17. Basilion EV, Kilima PM, Mecaskey JW, , 2005. Simplification and improvement of height-based azithromycin treatment for paediatric trachoma. Trans R Soc Trop Med Hyg 99: 612.[Crossref]
  18. Munoz B, Solomon AW, Zingeser J, Barwick R, Burton M, Bailey R, Mabey D, Foster A, West SK, , 2003. Antibiotic dosage in trachoma control programs: height as a surrogate for weight in children. Invest Ophthalmol Vis Sci 44: 14641469.[Crossref]
  19. World Health Organization, 2001. WHO Basic Malaria Microscopy. Geneva, Switzerland: World Health Organization.
  20. Meremikwu MM, Donegan S, Esu E, , 2008. Chemoprophylaxis and intermittent treatment for preventing malaria in children. Cochrane Database Syst Rev 2: CD003756.
  21. Sykes A, , 2009. Azithromycin plus artesunate versus artemether-lumefantrine for treatment of uncomplicated malaria in Tanzanian children: a randomized, controlled trial. Clin Infect Dis 49: 11951201.[Crossref]
  22. Bonate P, , 2000.  Analysis of Pretest-Postest Designs. Boca Raton, FL: Chapman and Hall/CRC.[Crossref]
  23. Fisher RA, , 1971. The Design of Experiments. New York, NY: Hafner Press.
  24. Meremikwu MM, Donegan S, Sinclair D, Esu E, Oringanje C, , 2012. Intermittent preventive treatment for malaria in children living in areas with seasonal transmission. Cochrane Database Syst Rev 2: CD003756.
  25. Wilson AL, , 2011. A systematic review and meta-analysis of the efficacy and safety of intermittent preventive treatment of malaria in children (IPTc). PLoS One 6: e16976.[Crossref]
  26. Gao D, Amza A, Nassirou B, Kadri B, Sippl-Swezey N, Liu F, Ackley SF, Lietman TM, Porco TC, , 2014. Optimal seasonal timing of oral azithromycin for malaria. Am J Trop Med Hyg 91: 936.[Crossref]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.16-0487
Loading
/content/journals/10.4269/ajtmh.16-0487
Loading

Data & Media loading...

  • Received : 15 Jun 2016
  • Accepted : 04 Nov 2016

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error